This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age.
The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval).
The secondary objectives are:
* To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine.
* To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day.
* To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).

开始日期2024-04-15

申办/合作机构

Stalicla SA

[+1]

NCT05203965

/ Recruiting早期临床1期IIT

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

开始日期2022-05-17

申办/合作机构

Yale University

[+1]

100 项与 Mavoglurant 相关的临床结果

登录后查看更多信息

100 项与 Mavoglurant 相关的转化医学

登录后查看更多信息

100 项与 Mavoglurant 相关的专利（医药）

登录后查看更多信息

项与 Mavoglurant 相关的文献（医药）

2025-05-01·MOVEMENT DISORDERS

Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials

Article

作者: Su, Dongning ; Zhang, Junjiao ; Feng, Tao ; Yin, Yixuan ; Yan, Rui ; Wan, Zhirong ; Zheng, Xiaoqing ; Cui, Yusha

Abstract:

Background:

Dyskinesia is a motor complication of Parkinson's disease (PD) posing therapeutic challenges. The optimal therapy for dyskinesia in PD has not been identified due to the lack of comprehensive evaluation of treatments.

Objective:

The aim was to compare the efficacy and safety of interventions for alleviating levodopa‐induced dyskinesia in PD.

Methods:

We conducted a Bayesian network meta‐analysis (NMA) by systematically searching PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov, and EudraCT databases up to April 1, 2024. The primary efficacy outcome was the change in scores on dyskinesia rating scales from baseline.

Results:

The study included 85 randomized controlled trials (RCT) involving 13,826 PD patients, comprising 39 interventions. Nine treatments were significantly more effective in reducing scores on dyskinesia rating scales than control (placebo, sham surgery, sham repetitive transcranial magnetic stimulation, or best medical treatment). Globus pallidus interna deep brain stimulation (GPi‐DBS) had the highest probability to be the most effective (standardized mean difference, 95% credible interval: −1.27, −1.65 to −0.88; surface under the cumulative ranking curve [SUCRA]: 97.4%), followed by levodopa–carbidopa intestinal gel infusion (SUCRA = 89.7%), subthalamic nucleus (STN)‐DBS (SUCRA = 89%), immediate‐release (IR) amantadine (SUCRA = 86.5%), pallidotomy (SUCRA = 84.9%), ADS‐5102 (SUCRA = 82.9%), clozapine (SUCRA = 77.2%), OS320 (SUCRA = 64.8%), and AFQ056 (SUCRA = 54.5%). GPi‐DBS was superior to STN‐DBS, and pallidotomy ranked higher than subthalamotomy. ADS‐5102 and OS320 had higher adverse event (AE) rates compared to control, whereas AFQ056 and ADS‐5102 were linked to more serious AEs.

Conclusions:

This RCT‐based NMA identifies and ranks nine efficacious interventions for dyskinesia in PD. GPi‐DBS may be the most effective therapy for treating dyskinesia, with IR amantadine ranking highest among oral medications. Novel anti‐dyskinetic medications are associated with less‐favorable tolerance profiles. © 2025 International Parkinson and Movement Disorder Society.

2025-04-02·Science Translational Medicine

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial

Article

作者: Gálvez, Bartolomé P. ; Kuper, Enrique I. ; Cha, Jang-Ho ; Walker, Ela ; Dolmetsch, Ricardo ; Berkheimer, Maria ; Gomez-Mancilla, Baltazar ; Gasparini, Fabrizio ; Dürsteler, Kenneth M. ; Gual, Antoni ; Corral, Ricardo M. ; Mosca, Daniel L. ; Pezous, Nicole ; Dumitras, Swati ; Herdener, Marcus ; Torrens, Marta ; Vogel, Marc

Metabotropic glutamate receptor 5 (mGluR5) is involved in cocaine reward processing and addiction. Preclinical studies suggest that blocking this receptor inhibits cocaine self-administration and seeking behavior in rodents. We assessed a selective noncompetitive antagonist of mGluR5 called mavoglurant in a phase 2 randomized, placebo-controlled clinical trial of 68 adults with cocaine use disorder. Study participants were randomly assigned in a 1:1 ratio to an up-titrating schedule of oral mavoglurant twice daily up to 200 mg for 98 days or placebo. The primary end point was the proportion of cocaine use days over the treatment period assessed by a retrospective self-report using Timeline Followback. Secondary end points were urine analysis of the cocaine metabolite benzoylecgonine and alcohol use measured by Timeline Followback assessment. Exploratory end points included testing for cocaine and alcohol metabolites in hair samples. The posterior probability of mavoglurant reducing cocaine use at the end of treatment was ≥99.0% for a treatment difference <0 and ≥36.6% for a treatment difference <−10%. The difference between mavoglurant and placebo was also assessed using analysis of covariance ( P = 0.021). Urine benzoylecgonine concentration was lower in the mavoglurant-treated group versus placebo ( P = 0.025); there was reduced alcohol consumption in the treatment group ( P = 0.072). Seventy-six percent (randomized set) and 79% (safety analysis set) of patients completed the final treatment visit. Adverse events in the treatment group were headache, dizziness, and nausea. In this small and short trial, mavoglurant reduced cocaine and alcohol use in patients with chronic cocaine use disorder.

2024-11-01·PSYCHOPHARMACOLOGY

The mGlu5 receptor negative allosteric modulator mavoglurant reduces escalated cocaine self-administration in male and female rats

Article

作者: Vendruscolo, Leandro F ; Acri, Jane B ; Vendruscolo, Janaina C M ; Volkow, Nora D ; Whiting, Kimberly E ; Koob, George F

Abstract:

Rationale:

Cocaine use disorder (CUD) is a brain disorder for which there is no Food and Drug Administration-approved pharmacological treatment. Evidence suggests that glutamate and metabotropic glutamate receptor subtype 5 (mGlu5) play critical roles in synaptic plasticity, neuronal development, and psychiatric disorders.

Objective:

In the present study, we tested the hypothesis that the mGlu5 receptor is functionally involved in intravenous cocaine self-administration and assessed the effects of sex and cocaine exposure history.

Methods:

We used a preclinical model of CUD in rats that were allowed long access (LgA; 6 h/day) or short access (ShA; 1 h/day) to intravenous cocaine (750 µg/kg/infusion [0.1 ml]) self-administration. Rats received acute intraperitoneal or oral administration of the mGlu5 receptor negative allosteric modulator mavoglurant (1, 3, and 10 mg/kg) or vehicle.

Results:

Both intraperitoneal and oral mavoglurant administration dose-dependently reduced intravenous cocaine self-administration in the first hour and in the entire 6 h session in rats in the LgA group, with no effect on locomotion. In the ShA group, mavoglurant decreased locomotion but had no effects on cocaine self-administration. We did not observe significant sex × treatment interactions.

Conclusions:

These findings suggest that the mGlu5 receptor is involved in escalated cocaine self-administration. These findings support the development of clinical trials of mavoglurant to evaluate its potential therapeutic benefits for CUD.

项与 Mavoglurant 相关的新闻（医药）

2025-07-07

·医药观澜

6家创新药公司完成新一轮融资！

根据公开信息，上周（6月30日~7月6日），全球范围内有至少6家致力于创新药研发的新锐公司宣布完成新一轮融资。通过梳理，这些获得资本青睐的新锐公司正在开发的产品包括小分子药物、多肽疗法等，聚焦的疾病领域涵盖了癌症、心血管疾病、肥胖症等代谢性疾病、眼科、自闭症等神经发育障碍疾病等等。麦科奥特融资轮次：D轮融资金额：超亿元7月3日，麦科奥特宣布完成超亿元D轮融资交割。本轮融资由浙商创投旗下临海启泽基金领投，所募集资金将重点用于推动核心管线研发、制剂产业化基地建设等方面，进一步提升麦科奥特在多肽创新药领域的研发能力。麦科奥特于2007年成立，专注于双功能和多功能特异性多肽药物研发，聚焦于心脑血管、代谢类疾病领域。新闻稿介绍，该公司已有7个创新药管线进入临床研发，包括1个临床3期阶段，3个临床2期阶段和3个临床1期阶段。拨康视云融资轮次：IPO融资金额：6.12亿港元7月3日，拨康视云（Cloudbreak Pharma）在港交所正式上市。配发结果显示，拨康视云全球发售6058.2万股股份，占发行完成后总股份的7.22%，其中香港公开发售1211.55万股，国际发售4846.65万股。最终发售价为每股10.10港元，获得款项总额为6.12亿港元，所得款项净额5.22亿港元。拨康视云是一家专注于眼科领域的临床阶段生物科技公司。此次港股IPO由建银国际、华泰国际担任联席保荐人。拨康视云拟将全球发售所得款项用于支持核心产品CBT-001（一款多激酶抑制剂）的持续临床研发活动、搭建生产设施及商业化活动等。同时加速眼科候选药物在全球的临床开发。Syntis Bio融资轮次：A轮融资金额：3300万美元7月1日，生物制药公司Syntis Bio宣布完成3300万美元的超额认购A轮融资，本轮融资由Cerberus Ventures领投。Syntis Bio公司专注于开发针对肥胖、糖尿病和罕见疾病的口服疗法，这些疗法专为在小肠（人体代谢控制、消化和药物吸收的关键部位）发挥靶向活性而设计。其主导项目SYNT-101为用于治疗肥胖的每日一次口服药物，作用原理是短暂地阻断小肠上部十二指肠的营养吸收，并将营养物质重定向到小肠下部，以刺激饱腹感和代谢调节激素（包括GLP-1）的自然分泌。这种被称为“十二指肠营养排除”的机制是胃旁路手术疗效的关键。Syntis Bio公司还在推进针对罕见代谢疾病和肠道相关疾病的治疗组合。FELIQS融资轮次：A轮融资金额：900万美元7月1日，FELIQS宣布完成900万美元A轮融资，本轮融资由一家美国大型制药公司与Beyond Next Ventures共同领投。FELIQS成立于2019年，专注于开发靶向氧化脂质的创新小分子疗法，用于治疗罕见儿童视网膜疾病。本轮融资资金将加速其主导产品FLQ-101的临床开发，该小分子候选药物旨在预防早产儿视网膜病变（ROP，一种可能导致早产儿失明的疾病），通过促进生理性视网膜血管生成，并抑制炎症及异常新生血管形成发挥作用。该产品已经获得美国FDA授予快速通道资格和孤儿药资格。维眸生物融资轮次：D2+轮融资金额：1.4亿元7月1日，瓯海科投公司下属基金温州瓯海湘投一村股权投资合伙企业（有限合伙）完成对维眸生物科技的D2+轮投资。本轮融资总额达1.4亿元，该资金用于多个眼科创新药临床试验推进、临床前管线研发及技术创新平台扩展。维眸生物是一家聚焦眼科治疗领域的临床阶段创新药研发公司，已经推动多个创新药产品进入或即将进入临床阶段，其产品维眸生物VVN461滴眼液获得中国NMPA纳入突破性治疗品种。VVN461是一款强效JAK1免疫调节剂，能够高活性抑制多个炎症细胞因子（cytokine）通路，从而治疗白内障术后炎症。Stalicla融资轮次：战略投资融资金额：200万瑞士法郎6月30日，专注于开发神经疾病新型小分子变构调节剂组合的临床阶段生物医药公司Addex Therapeutics宣布，其主导了对Stalicla的200万瑞士法郎投资。Stalicla专注于神经发育障碍（NDD）的治疗，将利用这笔资金推进其自闭症候选药物组合。Stalicla正准备启动其主导自闭症候选药物STP1及第二个资产的2期临床试验，两者均针对自闭症谱系障碍（ASD）特定亚群患者。Stalicla还在推进其STP7项目（mavoglurant），一种mGluR5负向变构调节剂（NAM）。期待在资本的助力下，更多前沿疗法和技术能够更快惠及患者。参考资料：[1]各公司官网及公开资料版权说明：本文欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

IPO临床3期临床2期

2025-06-30

·GlobeNewswire-Health Care

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C and the partnering of key programs. This financing underscores investor confidence in Stalicla’s innovative DEPI precision neuro platform and its portfolio of precision autism assets, STP1 and STP2. The company is also progressing its STP7 (mavoglurant) program, the most clinically advanced mGluR5 negative allosteric modulator, having concluded a Phase 3 enabling drug-drug interaction study in October 2024. The Phase 3 development continues to be financed by National Institute of Health-National Institute on Drug Abuse (NIH-NIDA) under a Collaborative Research and Development Agreement.As part of this financing, Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chairman. “This financing is a key step in securing our runway to reach a number of important milestones including our Series C financing,” said Lynn Durham, CEO of Stalicla. “We are grateful for the support from the Addex-led syndicate, which enables us to continue advancing our precision medicine programs and prepare for transformative clinical trials in autism and substance use disorders.” “Stalicla has built a world leading precision medicine neurodevelopment disorder platform and portfolio of clinical stage assets as well as adding tremendous value to their Phase 3 ready substance use disorders asset, STP7,” said Tim Dyer, CEO of Addex and Chairman of Stalicla. “We look forward to supporting Lynn Durham and her team as they bring these important medicines to patients.” About STALICLA: Stalicla SA, a Swiss clinical stage biopharmaceutical company, has raised over $50m to date in equity and more than $30m in non-dilutive funding to propel its mission to transform the landscape of neurodevelopmental disorder (NDD) treatments. The company has established a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, enabling the advancement of personalized treatment options. Currently, Stalicla is preparing to initiate Phase 2 trials for its leading NDD asset, STP1, along with a second asset, both targeting specific subpopulations within autism. Additionally, STP7 (Mavoglurant) is progressing towards Phase 3 trials, with full funding provided by the US government. For more information, please visit: www.stalicla.com. About Addex Therapeutics Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, please visit www.addextherapeutics.com Contacts: STALICLA SALynn Durham Founder & Chief Executive Officerlynn.durham@stalicla.com Media & InvestorsChris MaggosCohesion Bureauchris.maggos@cohesionbureau.com+41 79 367 62 54 Attachment STALICLA Financing PR_250630_Final

临床3期临床2期

2025-06-30

·GlobeNewswire-Health Care

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of autism focused drug candidates, support the partnering of certain assets and its series C financing as well as general corporate activities. As part of the Addex-led financing, Addex CEO, Tim Dyer, has been appointed to Stalicla’s Board of Directors and nominated as Chairman. “This strategic investment underscores Addex’s commitment to advancing innovative treatments for CNS disorders and builds on our 20% equity holding in Neurosterix. Stalicla has built a world leading precision medicine platform in neurodevelopmental disorders, backed by a strong portfolio of clinical-stage assets,” said Tim Dyer, CEO of Addex. “We look forward to providing our industry expertise to support the Stalica team as they bring forward these new treatment options for this underserved patient population.” The investment in Stalicla reinforces Addex’s strategy to support the advancement of precision therapeutics in CNS disorders. Stalicla is preparing to launch Phase 2 trials for its lead autism candidate STP1 and a second asset, both targeting specific subpopulations within autism spectrum disorder (ASD). Stalicla is also advancing its STP7 program (mavoglurant), an mGluR5 NAM, for cocaine use disorders under a Collaborative Research and Development Agreement (CRADA) with the NIH’s National Institute on Drug Abuse (NIDA). This program is the most advanced treatment candidate in development for this indication. “We are delighted to welcome Addex and its syndicate of investors to Stalicla. Addex brings a wealth of life science expertise and we look forward to working with them to build significant value for our shareholders,” said Lynn Durham, CEO of Stalicla. “Stalicla is poised to advance a number of assets into phase 2 clinical studies for subpopulations of patients with ASD and is committed to transforming the lives of these patients and their families.” About StaliclaStalicla SA, a Swiss clinical stage biopharmaceutical company, has raised over $50m to date in equity and more than $30m in non-dilutive funding to propel its mission to transform the landscape of neurodevelopmental disorder (NDD) treatments. The company has established a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, enabling the advancement of personalized treatment options. Currently, Stalicla is preparing to initiate Phase 2 trials for its leading NDD asset, STP1, along with a second asset, both targeting specific subpopulations within autism. Additionally, STP7 (mavoglurant) is progressing towards Phase 3 trials, with full funding provided by the US government. About Addex TherapeuticsAddex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

临床2期临床3期

100 项与 Mavoglurant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Mavoglurant	-	DB13004

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
物质滥用	临床3期	美国	National Institute on Drug Abuse	2023-03-08
物质滥用	临床3期	美国	Stalicla SA	2023-03-08
脆性X综合征	临床3期	美国	Novartis Pharmaceuticals Canada, Inc.	2011-11-01
脆性X综合征	临床3期	澳大利亚	Novartis Pharmaceuticals Canada, Inc.	2011-11-01
脆性X综合征	临床3期	比利时	Novartis Pharmaceuticals Canada, Inc.	2011-11-01
脆性X综合征	临床3期	丹麦	Novartis Pharmaceuticals Canada, Inc.	2011-11-01
脆性X综合征	临床3期	法国	Novartis Pharmaceuticals Canada, Inc.	2011-11-01
脆性X综合征	临床3期	德国	Novartis Pharmaceuticals Canada, Inc.	2011-11-01
脆性X综合征	临床3期	以色列	Novartis Pharmaceuticals Canada, Inc.	2011-11-01
脆性X综合征	临床3期	意大利	Novartis Pharmaceuticals Canada, Inc.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03327792 (CTgov)	临床1期	致幻	34	Mavoglurant (200 mg Mavoglurant)	糧願餘壓鏇膚醖衊艱積 = 獵壓淵膚遞選淵糧衊鬱襯醖遞築糧築廠衊鑰淵 (餘醖製遞壓膚憲艱齋願, 網範糧鑰願夢願遞遞窪 ~ 鹹醖網鬱網顧簾糧膚膚) 更多	-	2024-08-06
				Placebo (Placebo)	糧願餘壓鏇膚醖衊艱積 = 膚鑰糧壓淵鑰鏇壓選蓋襯醖遞築糧築廠衊鑰淵 (餘醖製遞壓膚憲艱齋願, 蓋醖壓積獵願願餘鏇製 ~ 膚夢獵積廠鑰繭鏇餘餘) 更多
NCT02920892 (FX-LEARN, CTgov)	临床2期	脆性X综合征	110	placebo+AFQ056 (Placebo Comparator: Double-Blind Placebo With Language Intervention)	製壓蓋窪夢壓願夢淵憲(廠繭壓網蓋構窪鏇願糧) = 齋選範願構簾衊網鬱網構餘醖製鹽襯憲衊鹹窪 (夢齋鹹蓋餘窪鑰鹹範壓, 範鬱構構鹽構廠壓簾衊 ~ 衊鬱願鬱簾窪積憲製選) 更多	-	2023-10-10
				AFQ056 (Experimental: Double-Blind AFQ056 With Language Intervention)	製壓蓋窪夢壓願夢淵憲(廠繭壓網蓋構窪鏇願糧) = 壓鏇繭襯選遞糧鹹襯鏇構餘醖製鹽襯憲衊鹹窪 (夢齋鹹蓋餘窪鑰鹹範壓, 廠選範醖衊糧夢淵襯淵 ~ 鹽襯鏇蓋淵鏇憲遞繭糧) 更多
NCT03242928 (CTgov)	临床2期	可卡因相关疾病 \| 全身性肉碱缺乏症	68	AFQ056 (AFQ056)	積艱選壓鬱築廠衊願選(遞淵壓鹹艱醖廠憲膚廠) = 鏇積憲廠範積遞築鬱顧製憲繭築餘選觸壓鬱鹽 (鑰齋願齋廠網夢醖衊築, 0.027) 更多	-	2021-02-04
				Placebo (Placebo)	積艱選壓鬱築廠衊願選(遞淵壓鹹艱醖廠憲膚廠) = 憲鹹廠壓製醖淵齋廠憲製憲繭築餘選觸壓鬱鹽 (鑰齋願齋廠網夢醖衊築, 0.024) 更多
WPC2019	N/A	-	485	Mavoglurant (AFQ056)	糧膚繭襯齋襯願鬱糧繭(獵艱願鏇壓衊鹹夢觸醖) = 淵鑰顧艱願襯積鏇齋憲襯糧廠鏇獵構網淵鹹範 (鑰鑰鹹構鬱糧範獵築顧, -0.65 ~ 0.11) 更多	不佳	2019-06-03
				Placebo	糧膚繭襯齋襯願鬱糧繭(獵艱願鏇壓衊鹹夢觸醖) = 觸壓積壓範鹹齋膚願膚襯糧廠鏇獵構網淵鹹範 (鑰鑰鹹構鬱糧範獵築顧, -0.09 ~ 0.66) 更多
NCT01348087 (Pubmed \| Sci Rep) 人工标引	临床2期	脆性X综合征	267	mavoglurant	遞網獵製衊築簾鏇構製(遞範壓繭積鏇艱齋醖夢) = 鏇鹹膚遞淵鹽遞願積蓋壓鏇膚繭淵餘積餘觸廠 (餘窪觸膚壓鬱範齋鏇蓋 ) 更多	不佳	2018-11-19
NCT01813019 (Pubmed \| Adv Ther) 人工标引	临床2期	强迫症	50	mavoglurant	範顧壓選範選壓淵網膚(鬱鹹觸壓觸鹽構獵齋衊) = 壓淵窪餘構夢鹹蓋觸夢獵製選餘觸願鏇醖構製 (選夢艱鑰壓鹹鹹鏇築窪 ) 更多	不佳	2017-02-01
				Placebo	範顧壓選範選壓淵網膚(鬱鹹觸壓觸鹽構獵齋衊) = 構鏇壓築襯願夢繭獵夢獵製選餘觸願鏇醖構製 (選夢艱鑰壓鹹鹹鏇築窪 ) 更多
NCT01813019 (CTgov)	临床2期	强迫症	50	Placebo (Placebo)	鏇壓範壓餘積艱繭膚鏇(顧襯鑰築鏇鏇齋廠築襯) = 夢衊積鹽齋願選憲醖網範蓋鹽繭齋築衊餘範鹹 (鹽廠糧淵憲夢遞鹹鏇構, 1.78) 更多	-	2016-07-21
				AFQ056 (AFQ056)	鏇壓範壓餘積艱繭膚鏇(顧襯鑰築鏇鏇齋廠築襯) = 齋獵鹽製鑰壓鬱壓鏇衊範蓋鹽繭齋築衊餘範鹹 (鹽廠糧淵憲夢遞鹹鏇構, 1.75) 更多
NCT01385592 (Pubmed) 人工标引	临床2期	药物性运动障碍 \| 帕金森病	-	Mavoglurant	齋顧鏇襯簾衊築艱鏇遞(簾製遞遞憲壓觸網遞構) = did not reach statistical significance 願鏇憲網淵壓衊衊遞壓 (廠廠膚鹽壓糧鬱憲憲鬱 )	不佳	2016-07-01
				Placebo
NCT01253629 (Pubmed \| Sci Transl Med) 人工标引	临床2期	脆性X综合征	314	Mavoglurant	窪築鹽製廠襯構獵蓋觸(餘鹽選積餘鹹糧製簾鏇) = Neither of the studies achieved 製糧顧醖膚窪製鬱繭艱 (製窪憲蓋鏇窪鏇願網製 )	不佳	2016-01-13
				Placebo
NCT01357239 (CTgov)	临床2期	脆性X综合征	139	Placebo	壓夢願憲築簾築鑰壓構(餘製範鹹遞積構鏇選淵) = 醖夢齋範獵遞憲淵觸觸鑰鑰襯積糧鹽獵簾觸觸 (齋範鬱糧醖夢衊網窪選, 3.88) 更多	-	2015-05-12